4.3 Article

Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers

Journal

ONCOTARGET
Volume 6, Issue 12, Pages 10487-10497

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.3402

Keywords

centrosome amplification; triple negative breast cancer; metastasis; disease prognosis

Funding

  1. National Cancer Institute at the National Institutes of Health [U01 CA179671, R01 CA169127]

Ask authors/readers for more resources

Centrosome amplification (CA), a cell-biological trait, characterizes pre-neoplastic and pre-invasive lesions and is associated with tumor aggressiveness. Recent studies suggest that CA leads to malignant transformation and promotes invasion in mammary epithelial cells. Triple negative breast cancer (TNBC), a histologically-aggressive subtype shows high recurrence, metastases, and mortality rates. Since TNBC and non-TNBC follow variable kinetics of metastatic progression, they constitute a novel test bed to explore if severity and nature of CA can distinguish them apart. We quantitatively assessed structural and numerical centrosomal aberrations for each patient sample in a large-cohort of grade-matched TNBC (n = 30) and non-TNBC (n = 98) cases employing multi-color confocal imaging. Our data establish differences in incidence and severity of CA between TNBC and non-TNBC cell lines and clinical specimens. We found strong correlation between CA and aggressiveness markers associated with metastasis in 20 pairs of grade-matched TNBC and non-TNBC specimens (p < 0.02). Time-lapse imaging of MDA-MB-231 cells harboring amplified centrosomes demonstrated enhanced migratory ability. Our study bridges a vital knowledge gap by pinpointing that CA underlies breast cancer aggressiveness. This previously unrecognized organellar inequality at the centrosome level may allow early-risk prediction and explain higher tumor aggressiveness and mortality rates in TNBC patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma In Situ

Karuna Mittal, Michael S. Toss, Guanhao Wei, Jaspreet Kaur, Da Hoon Choi, Brian D. Melton, Remus M. Osan, Islam M. Miligy, Andrew R. Green, Emiel A. M. Janssen, Havard Soiland, Keerthi Gogineni, Upender Manne, Padmashree Rida, Emad A. Rakha, Ritu Aneja

CLINICAL CANCER RESEARCH (2020)

Article Oncology

A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy

Frank A. Vicini, G. Bruce Mann, Chirag Shah, Sheila Weinmann, Michael C. Leo, Pat Whitworth, Rachel Rabinovitch, Mylin A. Torres, Julie A. Margenthaler, David Dabbs, Jess Savala, Steven C. Shivers, Karuna Mittal, Fredrik Warnberg, Troy Bremer

Summary: This study aimed to identify women with DCIS who have a low risk of IBR after BCS and can omit RT, as well as those with elevated IBR risk remaining after BCS plus RT, by evaluating a novel biosignature for a residual risk subtype (RRt). Patients were classified into three risk groups based on the biosignature and DS, and IBR rates were assessed by risk group and treatment. The novel biosignature identified three distinct risk profiles: Low Risk, Elevated Risk, and Residual Risk, highlighting the need for different treatment approaches for each group.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

No Data Available